外周动脉疾病患者心肌梗死的发生率、特征与结局:EUCLID试验分析
EUCLID试验纳入13 885例外周动脉疾病患者,随机接受替格瑞洛或氯吡格雷单药治疗,中位随访30个月。心肌梗死发生率为4.9%(每100患者年2.4次事件),以1型为主,2型占三分之一。发生心肌梗死与心血管死亡和需住院的急性肢体缺血独立相关。
要点
- 外周动脉疾病患者中位随访30个月心肌梗死发生率约5%
- 1型心肌梗死最常见(59.3%),但2型约占三分之一(34.6%)
- 发生心肌梗死后心血管死亡风险增加9倍,急性肢体缺血住院风险增加2.5倍
核心结论
- 症状性外周动脉疾病患者中位随访30个月约5%发生心肌梗死,以1型最常见,但2型约占三分之一。
- 发生心肌梗死与外周动脉疾病患者心血管死亡和需住院的急性肢体缺血独立相关。
研究设计与样本
- EUCLID为双盲随机临床试验,在28个国家811个中心随机13 885例症状性外周动脉疾病患者接受替格瑞洛或氯吡格雷单药治疗。
- 入组标准为踝臂指数≤0.80或既往下肢血运重建,中位随访30个月,本次分析评估随访期间心肌梗死发生情况。
主要发现
- 13 885例患者中,9997例(72.0%)为男性,中位年龄66(60-73)岁。
- 中位随访30个月期间,683例(4.9%;每100患者年2.4次事件)发生心肌梗死。
- 683例心肌梗死中,1型405例(59.3%)、2型236例(34.6%)、4a型14例(2.0%)、3型12例(1.8%)、4b型11例(1.6%)、5型5例(0.7%)。
- 发生心肌梗死者年龄更大(中位69岁 vs 66岁),糖尿病比例更高(51.1% vs 37.8%),既往下肢血运重建比例更高(68.2% vs 56.1%)。
- 随机化后心肌梗死与心血管死亡独立相关(校正HR 9.0;95%CI 7.3-11.2;P<.001),与需住院的急性肢体缺血独立相关(校正HR 2.5;95%CI 1.3-5.0;P=.008)。
临床怎么用
- 外周动脉疾病患者应视为心肌梗死高危人群,需关注1型和2型心肌梗死的识别与管理。
- 发生心肌梗死后应警惕心血管死亡和急性肢体缺血风险升高,加强相应监测。
局限性
- 原文未报告本分析的局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with peripheral artery disease (PAD) are at high risk for myocardial infarction (MI). OBJECTIVE: To characterize the incidence and types of MI in a PAD population, identify factors associated with MI, and determine the association of MI with cardiovascular mortality and acute limb ischemia. DESIGN, SETTING, AND PARTICIPANTS: The Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease (EUCLID) was a double-blind randomized clinical trial conducted at 811 sites in 28 countries that randomized 13 885 patients with symptomatic PAD to monotherapy with ticagrelor or clopidogrel. Participants had an ankle-brachial index (ABI) of 0.80 or less or previous lower extremity revascularization. Median follow-up was 30 months. For these analyses, patients were evaluated for MI occurrence during follow-up irrespective of treatment. Data were analyzed from June 2017 to September 2018. MAIN OUTCOMES AND MEASURES: An adjudication clinical events committee classified MI as type 1 (spontaneous), type 2 (secondary), type 3 (sudden cardiac death), type 4a (less than 48 hours after percutaneous coronary intervention), type 4b (definite stent thrombosis), or type 5 (less than 72 hours after coronary artery bypass graft). A multivariate regression model was developed by stepwise selection to identify factors associated with MI, and a time-dependent multivariate Cox regression analysis was performed to determine the association of MI with cardiovascular death and acute limb ischemia requiring hospitalization. RESULTS: Of the 13 885 patients included in this analysis, 9997 (72.0%) were male, and the median (interquartile range) age was 66 (60-73) years. Myocardial infarction occurred in 683 patients (4.9%; 2.4 events per 100 patient-years) during a median follow-up of 30 months. Patients experiencing MI were older (median [interquartile range] age, 69 [62-75] vs 66 [60-72] years), more likely to have diabetes (349 of 683 [51.1%] vs 4996 of 13 202 [37.8%]) or a previous lower extremity revascularization (466 of 683 [68.2%] vs 7409 of 13 202 [56.1%]), and had a lower ABI (if included by ABI) compared with censored patients. Of the 683 patients with MI during follow-up, the most common MI type was type 1 (405 [59.3%]), followed by type 2 (236 [34.6%]), type 4a (14 [2.0%]), type 3 (12 [1.8%]), type 4b (11 [1.6%]), and type 5 (5 [0.7%]). Postrandomization MI was independently associated with cardiovascular death (adjusted hazard ratio, 9.0; 95% CI, 7.3-11.2; P < .001) and acute limb ischemia requiring hospitalization (adjusted hazard ratio, 2.5; 95% CI, 1.3-5.0; P = .008). CONCLUSIONS AND RELEVANCE: Approximately 5% of patients with symptomatic PAD had an MI during a median follow-up of 30 months. Type 1 MI (spontaneous) was the most common MI type; however, one-third of MIs were type 2 MI (secondary). More research is needed to identify therapies to reduce the risk of MI in patients with PAD and to improve management of type 2 MI. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01732822.
引用
- Olivier CB, Mulder H, Hiatt WR, et al. Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial. JAMA Cardiol. 2019. PMID: 30540355. doi:10.1001/jamacardio.2018.4171
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。